Comprehensive medicinal chemistry III

Print version:

volume 1. General perspective : the future of drug discovery

volume 2. Drug discovery technologies

volume 3. In silico drug discovery tools

volume 4. Experimental ADME and toxicology

volume 5. Cancer, immunology and inflammation, and infectious disease

volume 6. Biologics medicine

volume 7. CNS, pain, metabolic syndrome, cardiovascular, tissue fibrosis and urinary incontinence

volume 8. Case histories in recent drug discovery. 9780128032015v1_WEB.pdf; Front Cover; COMPREHENSIVE MEDICINAL CHEMISTRY III; COMPREHENSIVE MEDICINAL CHEMISTRY III; Copyright; PREFACE; EDITORS-IN-CHIEF: BIOGRAPHIES; CONTRIBUTORS TO VOLUME 1; CONTENTS OF ALL VOLUMES; EDITORIAL BOARD; GENERAL PERSPECTIVE

THE FUTURE OF MEDICINAL CHEMISTRY; Introduction; PERMISSION ACKNOWLEDGMENTS; 1.01

Academic Drug Discovery Centers: Key Players in the Future of the Pharmaceutical Industry; 1.01.1 Pharmaceutical Industry Challenges: Productivity, Cost, Politics, and Patent Expirations; 1.01.2 The Bayh-Dole Act of 1980: A Catalyst for Academic Drug Discovery 1.01.2.1 The Role of Academic Drug Discovery Centers; 1.01.2.2 Academic Drug Discovery Center Structure and Function; 1.01.2.3 Founder Focused Academic Drug Discovery Centers; 1.01.2.4 Research Coordination Academic Drug Discovery Centers; 1.01.2.5 Fully Integrated Academic Drug Discovery Centers; 1.01.2.6 US Academic Drug Discovery Centers; 1.01.2.7 Risks and Rewards of Academic Drug Discovery Centers; 1.01.3 Concluding Remarks; References; 1.02

Drug Repurposing Review; 1.02.1 Historical Perspective; 1.02.2 Successes: From Chance Clinical Findings to Determinate Strategy 1.02.3 Advantages and Disadvantages of Drug Repurposing; 1.02.3.1 Attritional Risk; 1.02.3.2 Cost; 1.02.3.3 Time; 1.02.3.4 Disadvantages; 1.02.4 Variants; 1.02.4.1 Repurposing of Generic Drugs; 1.02.4.2 Public/Private Partnerships for Repurposing of Abandoned Assets; 1.02.4.3 Off-Target Versus On-Target; 1.02.4.4 Rare Diseases; 1.02.5 Approaches to the Identification of Drug Repurposing Candidates; 1.02.5.1 Experimental Approaches; 1.02.5.1.1 Target-association screening; 1.02.5.2.2 Phenotypic screening; 1.02.5.2 Knowledge-Based Approaches; 1.02.5.2.1 Literature-based; 1.02.5.1.2 Ontologies 1.02.5.3 Retrospective Analysis; 1.02.6 Data Mining Approaches for the Prediction of Drug Repurposing Opportunities; 1.02.6.1 Data Types; 1.02.6.2 Data Processing; 1.02.6.3 Resources; 1.02.6.4 Validation; 1.02.6.5 Structure-Target Data Mining; 1.02.6.5.1 Chemical structure methods; 1.02.6.5.2 Protein structure methods; 1.02.6.5.3 Molecular docking and binding site similarity; 1.02.6.5.4 Drug-target interaction profiles; 1.02.6.6 Effects-Based Data Mining; 1.02.6.6.1 Genome-based; 1.02.6.6.2 Transcriptome-based; 1.02.6.6.3 Proteome-based; 1.02.6.6.4 Phenome-based; 1.02.6.7 Integrated Approaches 1.02.6.8 Practical Considerations; 1.02.7 Beyond Repurposing: Tailoring an Existing Drug for a New Use; References; 1.03

Human iPSC Models in Drug Discovery: Opportunities and Challenges; 1.03.1 Introduction; 1.03.1.1 Historical and Technological Advances; 1.03.1.2 Human Biology Context; 1.03.2 iPSCs ex vivo Disease Models; 1.03.2.1 Human iPSC-Derived Cell Models to Study Disease in Cellular- and Genomic-Relevant Contexts; 1.03.2.1.1 Patient iPSC differentiation into disease-relevant cell types; 1.03.2.1.2 Assessing disease mechanisms in complex genetic disorders 1.03.2.2 Integrative and Translational Research of Human Disease Etiology